← Back to Search

Exercise for Anxiety Disorders

N/A
Recruiting
Led By Kristin Szuhany, MD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 2 visit

Summary

This trial will study whether exercise can help people with high levels of anxiety and anxiety disorders by improving their ability to learn and remember things.

Who is the study for?
This trial is for adults aged 18-60 with a primary diagnosis of an anxiety disorder (generalized, panic, or social) and high anxiety sensitivity. Participants must be able to exercise safely and not be pregnant, using benzodiazepines, or have recent substance abuse issues. Stable psychiatric medication use for at least 4 weeks prior is required.
What is being tested?
The study compares the effects of physical activity versus sitting on fear learning in people with high anxiety sensitivity and disorders. It looks into how these activities affect their expectations, emotions, and stress responses after learning to overcome fear.
What are the potential side effects?
Since this trial involves exercise as an intervention, potential side effects may include typical risks associated with physical activity such as muscle strain or injury. Sitting has minimal risk but may involve discomfort from remaining stationary.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 2 visit
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 2 visit for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Heart rate (HR)
Skin Conductance Response (SCR)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Exercise GroupExperimental Treatment1 Intervention
Participants who will be randomized to moderate intensity exercise after extinction (Day 1)
Group II: Seated groupPlacebo Group1 Intervention
Participants who will be randomized to sitting after extinction (Day 1)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Exercise
2016
Completed Phase 1
~820

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,415 Previous Clinical Trials
856,327 Total Patients Enrolled
Kristin Szuhany, MDPrincipal InvestigatorNYU Langone Health

Media Library

Exercise Clinical Trial Eligibility Overview. Trial Name: NCT05203731 — N/A
Panic Attacks Research Study Groups: Exercise Group, Seated group
Panic Attacks Clinical Trial 2023: Exercise Highlights & Side Effects. Trial Name: NCT05203731 — N/A
Exercise 2023 Treatment Timeline for Medical Study. Trial Name: NCT05203731 — N/A
~0 spots leftby Jan 2025